GRI Bio filings document a clinical-stage biotechnology issuer developing Natural Killer T cell modulators and the public-company events tied to that business. The filings include 8-K disclosures covering GRI-0621 clinical trial updates in idiopathic pulmonary fibrosis, financial-result releases and press-release exhibits furnished under results of operations and other-events items.
The filing record also details capital structure and governance matters, including at-the-market common stock offering agreements and prospectus supplements, legal opinions for share issuance, certificate amendments for a reverse stock split, Nasdaq Capital Market compliance notices, special meeting voting results and adjustments affecting common stock, warrants, convertible securities and equity incentive plans.
GRO Bio, Inc. received an amended Schedule 13G from Lincoln Alternative Strategies LLC reporting that it now beneficially owns 0 shares of GRO Bio common stock, representing 0% of the class. The filer confirms it owns 5 percent or less of the company’s common stock.
Lincoln Alternative reports no sole or shared voting or dispositive power over any GRO Bio shares and certifies the securities are not held to change or influence control of the issuer. The filing formally updates regulatory records to reflect the firm’s lack of beneficial ownership.
GRI Bio, Inc. filed a current report describing that it issued a press release on February 4, 2026. The release reiterates the company’s financial results for fiscal year 2025 and summarizes key recent business highlights.
The press release is furnished as Exhibit 99.1 and is not incorporated by reference into other SEC filings or deemed filed for liability purposes.
GRI Bio, Inc. is a clinical‑stage biopharmaceutical company developing immune‑modulating therapies for inflammatory, fibrotic and autoimmune diseases, led by oral iNKT‑cell inhibitor GRI‑0621 for idiopathic pulmonary fibrosis (IPF) and dNKT‑cell agonist GRI‑0803 for lupus.
A 35‑patient Phase 2a IPF trial of GRI‑0621 met its primary safety endpoint and evaluated multiple biomarker and lung‑function measures, with no treatment‑related serious adverse events and generally manageable side effects. The company plans, subject to FDA input and additional funding, a Phase 2b study that could support conditional EU approval and potential U.S. registration.
GRI‑0803 showed disease‑modifying signals in preclinical lupus nephritis models, and the company aims to file an IND and start Phase 1a/1b studies in 2026. GRI emphasizes broad NKT‑cell biology expertise and a patent estate with expected expiries around 2032–2035.
The business remains highly dependent on raising substantial additional capital, and management has expressed substantial doubt about the company’s ability to continue as a going concern. The filing also highlights Nasdaq listing risk and previously identified material weaknesses in internal controls, only partially remediated.
GRI Bio, Inc. amended its at-the-market stock offering program with H.C. Wainwright & Co., increasing the potential aggregate offering price from $10,000,000 to up to an aggregate of $60,000,000 of common shares under its existing prospectus supplement.
The amendment, effective as of January 28, 2026, is supported by a new prospectus supplement filed on January 29, 2026 and related legal opinion from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Certain provisions of a December 11, 2025 Securities Purchase Agreement were waived to permit issuances under the updated at-the-market arrangement.
GRI Bio, Inc. is updating its at-the-market stock offering to permit sales of up to $60,000,000 of common stock through H.C. Wainwright & Co. as sales agent.
The company has already sold shares for an aggregate purchase price of $12,639,002.84 under the existing program. As of January 29, 2026, its public float was approximately $86.6 million, based on 1,445,015 shares of common stock held by non-affiliates. The stock last traded at $4.11 per share on the Nasdaq Capital Market on January 28, 2026.
GRI Bio, Inc. has filed a shelf registration on Form S-3 to offer up to $250,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. Specific terms and pricing will be set in future prospectus supplements.
The company’s common stock trades on The Nasdaq Capital Market under the symbol GRI, with a last reported price of $5.55 per share on January 26, 2026. On January 23, 2026, GRI Bio effected a one-for-28 reverse stock split, and share and warrant figures in the prospectus reflect this adjustment. As of January 26, 2026, 525,358 shares of common stock were outstanding.
GRI Bio is a clinical-stage biopharmaceutical company developing therapies for inflammatory, fibrotic and autoimmune diseases. Its lead candidate, GRI-0621, targets idiopathic pulmonary fibrosis, and the pipeline also includes GRI-0803 for autoimmune disorders such as lupus and multiple sclerosis. Net proceeds from future sales under the shelf are expected to be used for general corporate purposes, including working capital and other general and administrative needs.
GRI Bio, Inc. filed a report noting that it has released additional data from its Phase 2a clinical trial of GRI-0621 in patients with idiopathic pulmonary fibrosis. The company announced these clinical findings through a press release dated January 28, 2026.
The press release is included as Exhibit 99.1, meaning the detailed trial information and outcomes are provided in that attached document rather than in the body of this report.
GRI Bio, Inc. approved a 1-for-28 reverse stock split of its common stock through a certificate of amendment to its Delaware charter. The split becomes effective at 4:01 p.m. Eastern Time on January 23, 2026, with the stock expected to begin trading on a post-split basis on The Nasdaq Capital Market on January 26, 2026.
At the effective time, every 28 issued and outstanding common shares will automatically convert into 1 share, with no change to the par value. The company will also make proportional adjustments to the exercise prices and share amounts for all outstanding stock options, warrants, convertible securities, and shares under its stock incentive plans, while keeping the total number of authorized common shares unchanged.
Shareholders who would otherwise receive fractional shares will instead get a cash payment equal to the fraction multiplied by the closing sale price of the common stock on January 23, 2026, adjusted for the reverse split. The common stock will continue to trade on Nasdaq under the symbol “GRI”.
GRI Bio, Inc. received formal notice from Nasdaq that it has conditionally regained compliance with the stockholders’ equity listing standard. For companies on the Nasdaq Capital Market with a market value under $35 million and annual net income under $500,000, Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million in stockholders’ equity.
The company had previously been notified that it was out of compliance based on its Form 10-Q for the quarter ended September 30, 2025. Nasdaq’s latest notice removes the immediate delisting risk, but it warns that if GRI Bio does not continue to meet the equity requirement in future Exchange Act reports, its common stock may again face possible delisting.